

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 9, 2026

M69 pCMV pGL3 Luciferase

RRID:Addgene_17186

Type: Plasmid

Proper Citation

RRID:Addgene_17186

Plasmid Information

URL: <http://www.addgene.org/17186>

Proper Citation: RRID:Addgene_17186

Bacterial Resistance: Ampicillin

Vector Backbone Description: Backbone Marker:Moon Lab; Backbone Size:0; Vector Backbone:pCMV pGL3 Luciferase; Vector Types:Mammalian Expression, Luciferase; Bacterial Resistance:Ampicillin

Comments: Description: This is a home-cooked PGL3 Luciferase expression vector. Reference: Ajamete Kaykas.

Plasmid Name: M69 pCMV pGL3 Luciferase

Record Creation Time: 20220422T221958+0000

Record Last Update: 20260808T081228+0000

Ratings and Alerts

No rating or validation information has been found for M69 pCMV pGL3 Luciferase.

No alerts have been found for M69 pCMV pGL3 Luciferase.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Liang S, et al. (2021) MIR337-3p Enhances Mycobacterial Pathogenicity Involving TLR4/MYD88 and STAT3 Signals, Impairing VDR Antimicrobial Response and Fast-Acting Immunity. *Frontiers in immunology*, 12, 739219.

Jang H, et al. (2020) The Tumor Suppressor, p53, Negatively Regulates Non-Canonical NF- κ B Signaling through miRNA-Induced Silencing of NF- κ B-Inducing Kinase. *Molecules and cells*, 43(1), 23.

Zhu D, et al. (2018) Nanoparticles Based on Poly (α -Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy. *Molecular therapy : the journal of the American Society of Gene Therapy*, 26(10), 2443.